+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hemato Oncology Testing Market - Global Forecast 2026-2032- Product Image
Hemato Oncology Testing Market - Global Forecast 2026-2032- Product Image
Sale

Hemato Oncology Testing Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904518
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hemato Oncology Testing Market is projected to reach USD 5.90 Billion in 2026. It is expected to continue growing at a CAGR of 16.62%, reaching USD 14.90 Billion by 2032.

Hemato oncology testing is becoming a core pillar of precision cancer care as clinicians move beyond morphology-only diagnosis toward integrated genomic, immunophenotypic, cytogenetic, and measurable residual disease (MRD) assessment. The field is supported by the growing clinical burden of leukemia, lymphoma, and multiple myeloma, with IARC/WHO GLOBOCAN 2022 documenting a substantial global incidence of hematologic malignancies, including leukemia and non-Hodgkin lymphoma among the most frequently diagnosed blood cancers.

Demand is strongest where testing directly changes treatment selection, transplant planning, prognosis, and monitoring. Next-generation sequencing (NGS), flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), immunohistochemistry, karyotyping, and liquid biopsy workflows are increasingly used together to guide targeted therapies, CAR-T eligibility, bispecific antibody strategies, hematopoietic stem cell transplant decisions, and relapse surveillance.

Transformative Shifts in the Hemato Oncology Testing Landscape

The hemato oncology testing landscape is shifting from single-analyte testing to integrated diagnostic pathways that combine molecular profiling, cytogenetics, flow cytometry, pathology, and clinical data. This transition is being accelerated by updated disease classifications from the World Health Organization and International Consensus Classification, both of which emphasize genetic, immunophenotypic, and molecular features in defining hematologic malignancies.

Clinical adoption is also being reshaped by MRD-guided care, decentralization of selected high-complexity testing in advanced hospital laboratories, and increasing use of companion diagnostics. As payers and providers focus on outcomes, laboratories that can deliver faster turnaround times, validated assays, standardized pre-analytical processes, and clinically actionable reports are better positioned to support precision hematology programs.

Cumulative Impact of Artificial Intelligence in Hemato Oncology Testing

Artificial intelligence is having a cumulative impact across hemato oncology testing by improving image analysis, variant interpretation, workflow triage, and quality control. In digital pathology and hematopathology, AI-enabled tools can assist with cell classification, bone marrow smear assessment, lymph node evaluation, mitotic activity review, and prioritization of complex cases, while human expert review remains essential for diagnosis and clinical sign-out.

AI is also improving the usability of NGS and multi-omics data by supporting variant annotation, literature matching, evidence ranking, and correlation with curated clinical knowledge bases. The greatest near-term value lies in augmenting laboratory efficiency, reducing manual review burden, improving reproducibility, and helping clinicians interpret complex molecular profiles in the context of evolving treatment guidelines, approved therapies, and clinical trial eligibility.

Key Regional Insights Across Hemato Oncology Testing

Asia-Pacific is gaining momentum as China, Japan, India, South Korea, and Australia expand oncology infrastructure, molecular testing capacity, and access to targeted hematology treatments. Adoption is supported by large patient populations, rising cancer diagnosis rates, government-backed precision medicine programs in several countries, and increasing use of NGS, flow cytometry, FISH, and PCR in tertiary hospitals and reference laboratories.

North America remains a benchmark region due to strong reimbursement pathways for medically necessary molecular diagnostics, concentration of academic cancer centers, FDA-cleared testing platforms, and broad clinical trial activity in leukemia, lymphoma, and multiple myeloma. Europe benefits from established hematology networks, external quality assessment programs, accreditation-driven laboratory standards, and cross-border research collaboration, while Latin America is improving access through private diagnostic networks, regional oncology centers, and expanding molecular pathology services in major urban markets.

The Middle East is investing in cancer centers, genomic medicine, and specialized laboratory capacity, particularly in high-income Gulf markets where national health transformation programs are emphasizing advanced diagnostics and specialist care. Africa remains more heterogeneous, with progress concentrated in urban referral centers and persistent gaps in sample logistics, specialist availability, affordability, and pathology infrastructure, creating a clear need for scalable, cost-effective hemato oncology testing models that support early diagnosis and treatment selection.

Key Group Insights for Hemato Oncology Testing Adoption

ASEAN markets are advancing through hospital modernization, public-private laboratory partnerships, medical tourism hubs, and growing oncology awareness, although access varies widely between Singapore, Malaysia, Thailand, Indonesia, the Philippines, and Vietnam. The GCC is building high-capacity oncology and genomics programs supported by national health transformation strategies, investment in specialist care, and expanding use of advanced molecular diagnostics within tertiary healthcare systems.

The European Union supports harmonized quality expectations, research funding, cross-border clinical collaboration, and implementation of in vitro diagnostic regulation, which is raising evidence requirements for analytical performance, clinical validity, and post-market surveillance. BRICS countries represent a large-volume testing environment, led by China and India in diagnostic demand and by Brazil and South Africa as regional hubs for oncology services, while Russia continues to rely on specialized oncology institutions despite procurement and access constraints.

G7 countries continue to lead in innovation, clinical guideline development, reimbursement sophistication, accreditation practices, and adoption of advanced molecular diagnostics for hematologic malignancies. NATO member markets overlap with many high-income healthcare systems, where resilience of medical supply chains, cybersecurity for laboratory and genomic data, and continuity of diagnostic services are becoming strategic priorities for oncology care delivery.

Key Country Insights in Hemato Oncology Testing

The United States leads in advanced hemato oncology testing due to strong academic cancer networks, broad NGS adoption, FDA oversight, clinical laboratory regulation, and integration of companion diagnostics into oncology care. Canada emphasizes publicly funded access and centralized expertise through provincial cancer systems, while Mexico and Brazil are expanding private and public oncology testing capacity, with Brazil serving as a major Latin American center for hematology services, clinical research, and molecular diagnostics adoption.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are strengthening molecular tumor boards, hematology trial networks, national genomic initiatives, and reimbursement for clinically validated assays. Russia maintains specialized oncology centers but faces access and procurement constraints, while Germany and France remain particularly influential in laboratory quality, translational research, hematology guideline adoption, and standardized diagnostic pathways for leukemia, lymphoma, and myeloma.

China is scaling genomic testing rapidly through large hospital systems, national cancer programs, and expanding molecular laboratory capacity. India is expanding access through high-volume reference laboratories, oncology hospital chains, and improving awareness of precision diagnostics, while Japan and South Korea maintain advanced diagnostics, strong research ecosystems, and early adoption of precision hematology tools. Australia benefits from organized cancer care, clinical trial participation, high-quality pathology infrastructure, and established use of molecular testing in specialist hematology services.

Actionable Recommendations for Hemato Oncology Testing Leaders

Industry leaders should prioritize clinically actionable test menus that align with WHO classifications, NCCN- or ESMO-relevant biomarkers, MRD requirements, transplant decision points, and therapy selection pathways. Investment should focus on validated NGS panels, standardized multiparameter flow cytometry, rapid PCR/FISH workflows, cytogenetic capabilities, and integrated reporting that links biomarkers to diagnostic classification, prognosis, and treatment implications.

Commercial and clinical success will depend on reducing turnaround time, strengthening sample logistics, improving payer evidence packages, and supporting clinician education on appropriate test utilization. Organizations should also build AI governance frameworks, validate algorithms across diverse populations and specimen types, ensure interoperability with laboratory information systems and electronic health records, and pursue partnerships with cancer centers, therapeutic developers, and reference laboratories.

Research Methodology for Hemato Oncology Testing Analysis

This executive summary is developed using a structured secondary-research approach that prioritizes verified sources such as WHO/IARC cancer statistics, regulatory agency publications, clinical guideline bodies, peer-reviewed literature, professional hematology and pathology standards, and public healthcare policy documents. The analysis emphasizes disease burden, clinical utility, technology adoption, regional healthcare infrastructure, regulatory direction, and laboratory workflow requirements.

Insights are triangulated across epidemiology, diagnostics adoption, treatment innovation, reimbursement trends, accreditation expectations, and laboratory operational needs. The methodology excludes unsupported market claims and focuses on evidence-backed signals relevant to hemato oncology testing, including NGS, flow cytometry, cytogenetics, FISH, PCR, MRD monitoring, companion diagnostics, immunohistochemistry, and AI-enabled laboratory operations.

Conclusion: The Future of Hemato Oncology Testing

Hemato oncology testing is moving rapidly toward integrated, data-rich, and therapy-directed diagnostics. The strongest opportunities are emerging where molecular profiling, immunophenotyping, cytogenetics, pathology, and MRD monitoring are embedded into routine clinical pathways and supported by clear reimbursement, accreditation, and quality standards.

As targeted therapies, cell therapies, and immunotherapies expand, demand for accurate and timely testing will continue to intensify. Organizations that combine scientific validity, operational scale, AI-enabled efficiency, robust data governance, and clinician-focused reporting will be best positioned to support the next phase of precision hematology diagnostics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hemato Oncology Testing Market, by Offering
7.1. Introduction
7.2. Instruments
7.3. Assay Kits & Reagents
7.4. Services
8. Hemato Oncology Testing Market, by Sample Type
8.1. Introduction
8.2. Bone Marrow
8.3. Peripheral Blood
8.4. Tissue Biopsy
9. Hemato Oncology Testing Market, by Technology
9.1. Introduction
9.2. Flow Cytometry
9.2.1. Immunophenotyping
9.2.2. Minimal Residual Disease Analysis
9.3. Fluorescence In Situ Hybridization
9.3.1. Chromosomal Abnormality Detection
9.3.2. Gene Fusion Detection
9.4. Immunohistochemistry
9.4.1. Chromogenic Immunohistochemistry
9.4.2. Fluorescent Immunohistochemistry
9.5. Next Generation Sequencing
9.5.1. RNA Sequencing
9.5.2. Targeted Gene Sequencing
9.5.3. Whole Exome Sequencing
9.5.4. Whole Genome Sequencing
9.6. Polymerase Chain Reaction
9.6.1. Digital PCR
9.6.2. Quantitative PCR
9.6.3. Reverse Transcription PCR
10. Hemato Oncology Testing Market, by Application
10.1. Introduction
10.2. Leukemia
10.2.1. Acute Lymphoblastic Leukemia
10.2.2. Acute Myeloid Leukemia
10.2.3. Chronic Lymphocytic Leukemia
10.2.4. Chronic Myeloid Leukemia
10.3. Lymphoma
10.3.1. Hodgkin Lymphoma
10.3.2. Non Hodgkin Lymphoma
10.4. Myelodysplastic Syndrome
10.5. Myeloma
11. Hemato Oncology Testing Market, by End User
11.1. Introduction
11.2. Academic & Research Centers
11.3. Diagnostic Laboratories
11.4. Hospitals & Clinics
11.5. Research Institutes
12. Hemato Oncology Testing Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Hemato Oncology Testing Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Hemato Oncology Testing Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Adaptive Biotechnologies Corporation
16.3. Agilent Technologies, Inc.
16.4. Akoya Biosciences, Inc.
16.5. ARUP Laboratories
16.6. Asuragen, Inc.
16.7. Becton, Dickinson And Company
16.8. Bio-Rad Laboratories, Inc.
16.9. Bio-Techne Corporation.
16.10. bioMérieux SA
16.11. BioView Ltd.
16.12. Danaher Corporation
16.13. DiaSorin S.p.A.
16.14. F. Hoffmann-La Roche AG
16.15. Foundation Medicine, Inc.
16.16. Fulgent Genetics, Inc.
16.17. Guardant Health, Inc.
16.18. HematoLogics, Inc.
16.19. Illumina, Inc.
16.20. Invivoscribe, Inc.
16.21. Laboratory Corporation of America Holdings
16.22. Menarini Silicon Biosystems S.p.A.
16.23. Mission Bio, Inc.
16.24. Natera, Inc.
16.25. NeoGenomics Laboratories, Inc.
16.26. Oxford Nanopore Technologies plc.
16.27. Personalis, Inc.
16.28. QIAGEN N.V.
16.29. Quest Diagnostics Incorporated
16.30. Siemens Healthineers AG
16.31. SOPHiA GENETICS SA.
16.32. Standard BioTools Inc.
16.33. Sysmex Corporation
16.34. Tempus AI, Inc.
16.35. Thermo Fisher Scientific Inc.
16.36. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL HEMATO ONCOLOGY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEMATO ONCOLOGY TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEMATO ONCOLOGY TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEMATO ONCOLOGY TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEMATO ONCOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL HEMATO ONCOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HEMATO ONCOLOGY TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNOPHENOTYPING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOPHENOTYPING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNOPHENOTYPING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CHROMOSOMAL ABNORMALITY DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CHROMOSOMAL ABNORMALITY DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CHROMOSOMAL ABNORMALITY DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL GENE FUSION DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL GENE FUSION DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL GENE FUSION DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CHROMOGENIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CHROMOGENIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CHROMOGENIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL FLUORESCENT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL FLUORESCENT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FLUORESCENT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TARGETED GENE SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TARGETED GENE SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TARGETED GENE SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL REVERSE TRANSCRIPTION PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL REVERSE TRANSCRIPTION PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL REVERSE TRANSCRIPTION PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 164. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 165. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 166. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 167. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 168. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 169. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 170. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 171. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 173. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 174. EUROPE HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 189. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 190. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 191. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 192. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 193. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 194. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 195. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 196. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 197. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 198. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 199. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 200. AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 204. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 205. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 206. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 207. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 208. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 209. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 210. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 211. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 212. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 213. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 214. ASEAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 217. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 218. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 219. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 220. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 221. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 222. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 223. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 224. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 225. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 226. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 227. GCC HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 243. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 244. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 245. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 246. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 247. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 248. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 249. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 250. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 252. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 253. BRICS HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 255. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 256. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 257. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 258. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 259. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 260. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 261. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 262. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 263. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 264. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 265. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 266. G7 HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 269. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 270. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 271. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 272. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 273. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 274. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 275. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 276. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 278. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 279. NATO HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 296. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 297. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 298. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 299. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 300. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 301. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 302. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 303. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 305. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 306. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 309. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 310. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 311. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 312. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 313. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 314. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 315. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 316. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 317. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 318. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 319. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 322. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 323. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 324. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 325. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 326. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 327. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 328. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 329. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 330. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 331. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 332. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 344. UNITED KINGD

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Akoya Biosciences, Inc.
  • ARUP Laboratories
  • Asuragen, Inc.
  • Becton, Dickinson And Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation.
  • bioMérieux SA
  • BioView Ltd.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche AG
  • Foundation Medicine, Inc.
  • Fulgent Genetics, Inc.
  • Guardant Health, Inc.
  • HematoLogics, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Menarini Silicon Biosystems S.p.A.
  • Mission Bio, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Nanopore Technologies plc.
  • Personalis, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • SOPHiA GENETICS SA.
  • Standard BioTools Inc.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.9 Billion
Forecasted Market Value ( USD ) by 2032 $ 14.9 Billion
Compound Annual Growth Rate16.6%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Hemato Oncology Testing - Global Strategic Business Report - Product Image

Hemato Oncology Testing - Global Strategic Business Report

  • Report
  • 375 Pages
  • Global
From
Hemato Oncology Testing Market Report 2026 - Product Image

Hemato Oncology Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Hemato Oncology Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Hemato Oncology Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Blockbuster Oncology Brands Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

Blockbuster Oncology Brands Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 96 Pages
  • Global
From
GCC Hemato Oncology Testing Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

GCC Hemato Oncology Testing Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 100 Pages
  • Middle East
From

About the Market

The Hemato Oncology Testing market within the Diagnostics industry is focused on the development and commercialization of tests that detect and monitor cancer and other hematological diseases. These tests are used to diagnose, monitor, and treat a variety of conditions, including leukemia, lymphoma, and myeloma. They are also used to detect and monitor the progression of cancer and other hematological diseases. The tests are used to identify genetic mutations, detect the presence of cancer cells, and monitor the effectiveness of treatments. The Hemato Oncology Testing market is highly competitive, with a number of companies offering a variety of tests. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Cepheid, GenMark Diagnostics, Hologic, Illumina, Myriad Genetics, Qiagen, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.